CytoSorbents Corporation (CTSO)

[Eltoro43]

Burnttoast, I condensed and modified your post for a few relatives that are also investors.

HemoDefend

HemoDefend is Closer to Commercialization with a New $3 million, 3-Year NHLBI Award. This Award, was announced in for CTSO in August. This will be used to fund a pivotal FDA clinical trial,and anticipate that that study will begin in Q1 2019.

The potential market for HemoDefend could be enormous. An estimated 80M -100M blood donations happen each year worldwide with each donation generating multiple blood transfusion products such as packed red blood cells (pRBCs), platelets, fresh frozen plasma, and cryoprecipitate.


The HemoDefend filter removes contaminants such as antibodies, free hemoglobin, cytokines, and bioactive lipids in packed red blood cells.
HemoDefend’s practical and effective ways to purify contaminated blood and reduce risk of transfusion-related adverse reactions is an objective of the NHLBI Award.

The significance of continued development of HemoDefend should not be underestimated. When that happens, it should be a wake-up call for investors value.